Exclusive Student Offer

Prime for Young Adults

Get a 6-month trial with premium college perks & fast delivery.

Start Free Trial
Listen Anywhere

Audible Standard Trial

Get 30 days of audiobooks free. Cancel anytime, keep your books.

Claim Free Books

On April 14, 2022, Dermapharm published the balance sheet for the most recent quarter that ended on December 31, 2021.

Earnings per share were estimated at EUR 1.33. In the same quarter of the previous year, EUR 0.450 per share was on the books.

In terms of sales, EUR 272.8 million was on the books in the past quarter. This equates to an increase of 25.87 percent over sales in the prior-year quarter. At that time, Dermapharm had sales of EUR 216.7 million.

Earnings per share for the full year were EUR 3.90. In the previous year, the company reported earnings of EUR 1.79 per share.

In terms of sales, EUR 943.85 million was reported. In the previous year, Dermapharm had sales of EUR 794.00 million.

In their estimates for the financial year, analysts had issued earnings of EUR 3.91 per share and sales of EUR 945.32 million.

Editorial office finanzen.net

Selected leverage products on Dermapharm Holding SEWith knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired lever and we will show you suitable products on Dermapharm Holding SE

Leverage must be between 2 and 20

No data

ttn-28

Get Audible 30-Day Free Trial

As an Amazon Associate, we earn from qualifying purchases.